Systemic Treatment with the Janus Kinase Inhibitor Baricitinib in Ocular Chronic Graft-versus-Host Disease
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Authors
- Edward W. Cowen (ORCID: https://orcid.org/0000-0003-1918-4324)
- Cody J. Peer (ORCID: https://orcid.org/0000-0001-9395-3473)
- Susan Vitale (ORCID: https://orcid.org/0000-0002-5972-6848)
- Chantal Cousineau-Krieger (ORCID: https://orcid.org/0000-0003-1008-8950)
- Aaron T. Zhao (ORCID: https://orcid.org/0000-0001-5638-8962)
- Debbie Payne
- M. Teresa Magone (ORCID: https://orcid.org/0000-0001-6370-6295)
- Steven Zivko Pavletic (ORCID: https://orcid.org/0000-0001-9111-9354)
- Taylor McManus (ORCID: https://orcid.org/0000-0002-1724-6109)
- William D. Figg (ORCID: https://orcid.org/0000-0003-2428-5613)
- Jacqueline Wiesehan Mays (ORCID: https://orcid.org/0000-0002-4472-9974)
- Annie Im
- Noa G. Holtzman (ORCID: https://orcid.org/0000-0002-5706-1109)
- Edmond J. FitzGibbon (ORCID: https://orcid.org/0000-0001-6855-7540)
- Janine Newgen
- Celestina Igbinosun
Institutions
- University of Miami (US)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (US)
- National Institute of Dental and Craniofacial Research (US)
- National Eye Institute (US)
- National Cancer Institute (US)
Publication Details
- Journal
- Ophthalmology Science
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1016/j.xops.2024.100627
- Citations
- 2
- Primary Topic
- Corneal Surgery and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Eli Lilly and Company
- National Institutes of Health
- National Eye Institute
- National Cancer Institute
- Office of Research on Women's Health
- NHLBI Division of Intramural Research